首页> 外国专利> POLYPEPTIDE CONJUGATE COMPRISING HUMAN FACTOR VII OR HUMAN FACTOR VIIA LIKE MOLECULES, NUCLEOTIDE SEQUENCE ENCODING THEREFOR, METHOD FOR PRODUCTION THEREOF AND USES THEREOF

POLYPEPTIDE CONJUGATE COMPRISING HUMAN FACTOR VII OR HUMAN FACTOR VIIA LIKE MOLECULES, NUCLEOTIDE SEQUENCE ENCODING THEREFOR, METHOD FOR PRODUCTION THEREOF AND USES THEREOF

机译:包含人因子VII或人因子VII类似分子的多肽缀合物,编码其的核苷酸序列,其制备方法及其用途

摘要

The present invention relates to novel factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates, to their preparation and use in therapy, in particular for the treatment of a variety of coagulation-related disorders. These novel polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide, wherein the amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non-polypeptide moiety has been introduced or removed. The conjugates of the present invention have one or more improved properties as compared to commercially available rFVIIa, including increased functional in vivo half-life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.
机译:本发明涉及新颖的因子VII(FVII)或因子VIIa(FVIIa)多肽缀合物,涉及它们的制备和在治疗中的用途,特别是用于治疗各种凝血相关疾病。这些新颖的多肽缀合物包含共价附于多肽的至少一个非多肽部分,其中该多肽的氨基酸序列与野生型FVII或FVIIa的氨基酸序列的不同之处在于,至少一个氨基酸残基包含用于所述多肽的连接基团。非多肽部分已被引入或去除。与市售的rFVIIa相比,本发明的缀合物具有一种或多种改善的性质,包括增加的体内功能性半衰期和/或血浆半衰期增加,和/或生物利用度增加和/或对蛋白水解降解的敏感性降低。

著录项

  • 公开/公告号IL150692B

    专利类型

  • 公开/公告日2010-03-28

    原文格式PDF

  • 申请/专利号IL150692

  • 发明设计人

    申请日2002-07-11

  • 分类号

  • 国家 IL

  • 入库时间 2022-08-21 18:46:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号